GLAUKOS CORP

Glaukos beats earnings and revenue expectations with $185.6 M sales, driving growth in micro‑injectable glaucoma therapies and investor optimism.

Glaukos Corporation, a leader in ophthalmic medical technology, celebrated its 10th anniversary on the New York Stock Exchange (NYSE) on June 25, 2025.

Glaukos Corporation reported a 25% increase in net sales for Q1 2025, exceeding revenue expectations despite a loss for the quarter, and reaffirmed its full-year guidance.

Glaukos Corporation reported a strong Q1 2025 with a 25% increase in net sales, exceeding revenue and earnings expectations, and reaffirming its full-year guidance.